Daprodustat, sold under the brand name Duvroq among others, is a medication used for the treatment of anemia due to chronic kidney disease (CKD). It is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is taken by mouth. By stabilizing hypoxia-inducible factor (HIF), Daprodustat increases endogenous erythropoietin production, which stimulates red blood cell formation. This mechanism offers an alternative to traditional erythropoiesis-stimulating agents (ESAs) and provides a potential treatment option for patients with anemia related to CKD.
Parent: Daprodustat
Parent: Daprodustat
Parent: Daprodustat
Parent: Daprodustat
Parent: Daprodustat
Parent: Daprodustat
Parent: Daprodustat
During the production and storage of Daprodustat, impurities may form, which must be controlled to ensure the medication’s safety and efficacy. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), set guidelines on permissible impurity levels in Daprodustat formulations.
Common side effects of Daprodustat include hypertension, gastrointestinal issues such as nausea and vomiting, and an increased risk of thromboembolic events. Patients may also experience dizziness or headaches. Monitoring by healthcare professionals is recommended to manage potential side effects.
Yes, Daprodustat has been approved in the EU for the treatment of anemia associated with chronic kidney disease in adult patients. Approval timelines and labeling may vary by country within the EU.
Yes, Daprodustat is approved by the U.S. Food and Drug Administration (FDA) for treating anemia due to chronic kidney disease in patients who are either on dialysis or not on dialysis.
The bioavailability of Daprodustat is relatively high, allowing for effective oral administration. Specific bioavailability values may vary, and healthcare providers consider this information when prescribing to ensure effective dosing.
